|
1.
|
|
13 p, 1.9 MB |
Nanoceria as Safe Contrast Agents for X-ray CT Imaging
/
García, Ana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cámara, Juan Antonio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Boullosa, Ana María (Networking Research Centre on Bioengineering) ;
Gustà, Muriel F. (Institut Català de Nanociència i Nanotecnologia) ;
Mondragón, Laura (Institut Català de Nanociència i Nanotecnologia) ;
Schwartz, Simon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Casals, Eudald (Wuyi University) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron) ;
Bastús, Neus G (Institut Català de Nanociència i Nanotecnologia) ;
Puntes, Víctor (Institut Català de Nanociència i Nanotecnologia)
Cerium oxide nanoparticles (CeONPs) have exceptional catalytic properties, rendering them highly effective in removing excessive reactive oxygen species (ROS) from biological environments, which is crucial in safeguarding these environments against radiation-induced damage. [...]
2023 -  10.3390/nano13152208
Nanomaterials, Vol. 13, Issue 15 (August 2023) , art. 2208
|
|
|
2.
|
|
21 p, 5.9 MB |
Oxidative Stress in Structural Valve Deterioration : A Longitudinal Clinical Study
/
Galiñanes, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Casós, Kelly (Hospital Universitari de Bellvitge) ;
Blasco-Lucas, Arnau (Hospital Universitari de Bellvitge) ;
Permanyer, Eduard (Centro Médico Teknon) ;
Máñez, Rafael (Hospital Universitari de Bellvitge) ;
Le Tourneau, Thierry (Université de Nantes) ;
Barquinero, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Schwartz, Simon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bottio, Tomaso (University Hospital of Padova (Pàdua, Itàlia)) ;
Roussel, Jean Christian (CHU de Nantes) ;
Fellah-Hebia, Imen (CHU de Nantes) ;
Sénage, Thomas (Université de Nantes) ;
Evangelista Masip, Arturo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Badano, Luigi P. (San Luca Hospital(Itàlia)) ;
Ruiz-Majoral, Alejandro (Hospital Universitari de Bellvitge) ;
Galli, Cesare (Avantea and Fondazione Avantea Onlus (Itàlia)) ;
Padler-Karavani, Vered (Tel Aviv University) ;
Soulillou, Jean-Paul (Centre Hospitalier Universitaire de Nantes) ;
Vidal Guitart, Xavier (Hospital Universitari Vall d'Hebron) ;
Cozzi, Emanuele (University Hospital of Padova (Pàdua, Itàlia)) ;
Costa, Cristina (Hospital Universitari de Bellvitge) ;
Universitat Autònoma de Barcelona
The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. [...]
2022 - 10.3390/biom12111606
Biomolecules, Vol. 12 (october 2022)
|
|
|
3.
|
|
25 p, 4.8 MB |
Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide
/
Cámara-Sánchez, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Díaz Riascos, Zamira Vanessa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García Aranda, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gener, Petra (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Giani-Alonso, Micaela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Royo, Miriam (Institut de Química Avançada de Catalunya) ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Schwartz, Simon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona.
Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí"
Cancer maintenance, metastatic dissemination and drug resistance are sustained by cancer stem cells (CSCs). Triple negative breast cancer (TNBC) is the breast cancer subtype with the highest number of CSCs and the poorest prognosis. [...]
2022 - 10.3390/ijms231911760
International journal of molecular sciences, Vol. 23, Issue 19 (October 2022) , art. 11760
|
|
|
4.
|
|
13 p, 1.3 MB |
Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis
/
Bazzocco, Sarah (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Dopeso, Higinio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez-Barriocanal, Águeda (IRBLleida. Group of Molecular Oncology) ;
Anguita, Estefanía (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Nieto Raya, Rocio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Li, Jing (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Garcia-Vidal, Elia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Maggio, Valentina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rodrigues, Paulo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de Marcondes, Priscila Guimarães (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Schwartz, Simon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Aaltonen, Lauri A. (University of Helsinki) ;
Sánchez, Alex (Universitat de Barcelona. Departament d'Estadística) ;
Mariadason, John M. (La Trobe University. School of Cancer Medicine) ;
Arango, Diego (IRBLleida. Group of Molecular Oncology)
Cancer initiation and progression are driven by genetic and epigenetic changes. Although genome/exome sequencing has significantly contributed to the characterization of the genetic driver alterations, further investigation is required to systematically identify cancer driver genes regulated by promoter hypermethylation. [...]
2021 - 10.1186/s13148-021-01070-0
Clinical Epigenetics, Vol. 13 (april 2021)
|
|
|
5.
|
|
|
6.
|
|
12 p, 2.8 MB |
Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells
/
Gener, Petra (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Callejo, Patricia González (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrade, Fernanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rafael, Diana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Montero, Sara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sayós, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Schwartz, Simon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
There are remarkable similarities in the description of cancer stem cells (CSCs) and cancer cells with mesenchymal phenotype. Both cell types are highly tumorigenic, resistant against common anticancer treatment, and thought to cause metastatic growth. [...]
2018 - 10.1155/2018/4516454
Stem Cells International, Vol. 2018 (october 2018)
|
|
|
7.
|
|
20 p, 1.8 MB |
Extracellular Vesicles as Drug Delivery Systems in Cancer
/
Hernandez-Oller, Laia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrade, Fernanda (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Rafael, Diana (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Abasolo, Ibane (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Gener, Petra (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Schwartz, Simon (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Universitat Autònoma de Barcelona
Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. [...]
2020 - 10.3390/pharmaceutics12121146
Pharmaceutics, Vol. 12 (november 2020)
|
|
|
8.
|
|
20 p, 2.7 MB |
Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells
/
Montero, Sara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrade, Fernanda (Universidade do Porto) ;
Martinez-Trucharte, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vilar-Hernández, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Quesada, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Xandri Monje, Helena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rafael, Diana (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Schwartz, Simon (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Universitat Autònoma de Barcelona
Structural maintenance of chromosomes protein 2 (SMC2) is a central component of the condensin complex involved in DNA supercoiling, an essential process for embryonic stem cell survival. SMC2 over-expression has been related with tumorigenesis and cancer malignancy and its inhibition is regarded as a potential therapeutic strategy even though no drugs are currently available. [...]
2020 - 10.3390/pharmaceutics12020185
Pharmaceutics, Vol. 12 (february 2020)
|
|
|
9.
|
|
1.9 MB |
AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells
/
Rafael, Diana (Universitat Autònoma de Barcelona) ;
Gener, Petra (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrade, Fernanda (Instituto de Salud Carlos III) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Montero, Sara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Fernández Caparrós, Yolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hidalgo, Manuel (Rosenberg Clinical Cancer Center Beth Israel Deaconess Medical Center) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Florindo, Helena F. (Universidade de Lisboa) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Schwartz, Simon (Instituto de Salud Carlos III) ;
Videira, Mafalda (Universidade de Lisboa) ;
Universitat Autònoma de Barcelona
Development of RNA interference-based therapies with appropriate therapeutic window remains a challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. [...]
2018 - 10.1080/10717544.2018.1461276
Drug Delivery, Vol. 25 (april 2018) , p. 961-972
|
|
|
10.
|
|
12 p, 2.9 MB |
The biological potential hidden in inclusion bodies
/
Gifre-Renom, Laia (Institut de Recerca i Tecnologia Agroalimentàries) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rafael, Diana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrade, Fernanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cano-Garrido, Olivia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Martinez-Trucharte, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ugarte-Berzal, Estefanía (Katholieke Universiteit Leuven. Department of Microbiology, Immunology and Transplantation) ;
Martens, Erik (Katholieke Universiteit Leuven. Department of Microbiology, Immunology and Transplantation) ;
Boon, Lise (Katholieke Universiteit Leuven. Department of Microbiology, Immunology and Transplantation) ;
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Opdenakker, Ghislain (Katholieke Universiteit Leuven. Department of Microbiology, Immunology and Transplantation) ;
Schwartz, Simon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Arís i Giralt, Anna (Institut de Recerca i Tecnologia Agroalimentàries) ;
Garcia-Fruitos, Elena (Institut de Recerca i Tecnologia Agroalimentàries)
Inclusion bodies (IBs) are protein nanoclusters obtained during recombinant protein production processes, and several studies have demonstrated their potential as biomaterials for therapeutic protein delivery. [...]
2020 - 10.3390/pharmaceutics12020157
Pharmaceutics, Vol. 12, issue 2 (2020) , art. 157
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
